Lineage Cell Therapeutics (LCTX)
Develops off-the-shelf cell-replacement therapies for retinal, spinal-cord, hearing and corneal disease.
Something off on this page? Send us feedback.
Develops off-the-shelf allogeneic cell-replacement therapies from pluripotent stem cells, generating collaboration and license-related revenue while candidates remain investigational. Its shared AlloSCOPE platform supports retinal, spinal-cord, hearing and corneal programs, with OpRegen licensed to Roche/Genentech.
Develops off-the-shelf, allogeneic cell-replacement therapies from pluripotent stem cells, using its AlloSCOPE manufacturing platform to create differentiated cells for damaged tissues. Revenue comes principally from collaboration, licensing and research obligations rather than product sales, with no approved therapy or established sales infrastructure.
The portfolio spans OpRegen retinal-pigment-epithelium cells for geographic atrophy, OPC1 oligodendrocyte progenitor cells for spinal-cord injury, ReSonance for hearing loss, COR1 for corneal disease, and early manufacturing and photoreceptor programs. Roche/Genentech holds worldwide rights to OpRegen, while internal programs share development and manufacturing work.
All therapeutic candidates remain investigational. Manufacturing is centered at its Jerusalem subsidiary, so commercialization depends on clinical results, regulatory review, specialized delivery, scalable cell production, collaborators and a single manufacturing site.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $50.8M · Total debt $2.3M · Total assets $106.2M · Shareholders' equity $60.9M
- Revenue
- $1.1M
- Operating income
- −$8.9M
- Net income
- $1.5M
No dividends on record.
| Institutions | 46.39% | 117.32M shares | |
|---|---|---|---|
| 136 holders · as of Jun 30, 2026 | |||
| Insiders | 27.40% | 69.29M shares | |
| 2 holders · as of Nov 14, 2025 | |||
| Other | 26.21% | 66.30M shares | |
| remainder | |||
252.91M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Neal C. BradsherInsider | 22.87% | 57.85M | filed Nov 14, 2025 |
Broadwood Capital IncInstitution | 19.60% | 49.56M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 5.21% | 13.19M | as of Jun 30, 2026 |
Chernett JoreyInsider | 4.53% | 11.45M | filed Sep 26, 2025 |
Vanguard Capital Management LLCInstitution | 3.58% | 9.05M | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- Biogen
SYFOVRE is the leading commercial treatment for geographic atrophy.
- AbbVie
C5 inhibition for geographic atrophy, plus retinal gene therapy.
- Regeneron
Phase 3 C5 therapy and a large retinal-specialist franchise.
- NervGen Pharma
Neuroreparative recovery therapy for spinal-cord injury.
- Sana Biotechnology
Hypoimmune iPSC islet-cell therapy and cell-engineering overlap.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Lineage Cell Therapeutics | $1.01 | −3.37% | $259.3M | — | — | 19.8 | −61.3% |
| Biogen | $226.80 | +0.64% | $33.30B | 39.9 | 17.1 | 3.3 | +3.4% |
| AbbVie | $267.14 | +0.73% | $468.77B | 74.8 | 17.6 | 7.3 | +10.2% |
| Regeneron | $806.36 | +0.31% | $82.82B | 19.9 | 13.3 | 5.3 | +16.7% |
| NervGen Pharma | $2.06 | −0.30% | $169.7M | — | — | — | — |
| Sana Biotechnology | $3.18 | −4.65% | $926.7M | — | — | — | — |
| Median | 39.9 | 17.1 | 5.3 | +10.2% |